LENZ Therapeutics
LENZ
94 hedge funds and large institutions have $573M invested in LENZ Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
131% more capital inflows, than outflows
Capital inflows: $67.9M | Capital outflows: $29.4M
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
21% more funds holding
Funds holding: 78 → 94 (+16)
4.1% more ownership
Funds ownership: 68.13% → 72.23% (+4.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
+$23.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.4M |
| 3 |
BlackRock
New York
|
+$6.88M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.25M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$8.23M |
| 2 |
Samsara BioCapital
Palo Alto,
California
|
-$6.75M |
| 3 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$3.31M |
| 4 |
Schonfeld Strategic Advisors
New York
|
-$2.55M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.47M |
LENZ Hedge Fund Activity: Q4 2024 in Review
94 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2024, worth a combined $573M — up 29% from $445M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LENZ positions and 8 closed out — a net gain of 16 holders — while 33 added to existing stakes and 20 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $23.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.23M sold.
- 94 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2024, up from 78 in Q3 2024.
- Funds reported $573M of LENZ Therapeutics stock for Q4 2024, up 29% quarter-over-quarter.
- 24 funds opened new LENZ Therapeutics positions in Q4 2024 and 8 closed out, a net change of +16 holders.
- The largest LENZ Therapeutics buyer in Q4 2024 was Paradigm Biocapital Advisors, an estimated $23.5M added.
- The largest LENZ Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $8.23M sold.
Based on aggregated 13F filings for Q4 2024.